$QURE

Potts Jeannette sold $145K of QURE

Potts Jeannette (Chief Legal Officer) sold 5,237 shares of uniQure N.V. (QURE) at $27.67 ($0.14M total) on 2026-06-15.

Original reporting
SEC EDGAR · Potts Jeannette
Published Jun 17, 2026, 8:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

This adds incremental transparency on insider activity but does not include operational, clinical, regulatory, or financial performance changes.

02

Market read

Traders may monitor for follow-on insider selling, but the disclosed transaction size and lack of accompanying fundamental catalysts suggest limited immediate trading impact.

03

What to watch

Insider sales can be driven by taxes, diversification, or pre-existing personal liquidity needs; the filing provides no rationale or forward guidance.

Relevance 4/10Novelty 5/10Timing: filed 2026-06-17 (covers sale dated 2026-06-15)

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V., reporting an officer’s open-market sale.

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure N.V. (QURE) disclosed an officer open-market sale: 5,237 shares sold on 2026-06-15 at $27.6700 for ~$144.9K.

Expected impact

Likely limited near-term impact; any reaction should be muted unless follow-on selling accelerates.

Evidence & confidence

Form 4 insider transactions are common and this one is modest in dollar value; absence of a 10b5-1 plan can raise attention but the disclosure alone rarely drives sustained repricing.

Market effects

No sector read-across; this is company-specific insider liquidity/portfolio activity.

None indicated.

None indicated.

Counterpoint

The lack of a pre-arranged 10b5-1 plan could be interpreted as less “scheduled” selling, potentially signaling management discretion rather than a planned cadence.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider sale disclosure.

  • Potts Jeannette

    Chief Legal Officer who sold 5,237 shares.

Related articles

$QUREMed

uniQure (QURE) Q2 2026 Earnings Call Transcript

uniQure (NASDAQ:QURE) reported Q2 2026 results and said the FDA aligned on submitting a Huntington’s disease AMT-130 BLA under accelerated approval in Q3 2026 using three-year data. Cash and investments were $810.3M at June 30, 2026 after a $259M follow-on. Q2 revenue was $5.8M, net loss $81.1M.

$QUREMed

Gene therapy shows benefits in all participants in Fabry clinical trial

uniQure said its investigational one-time gene therapy AMT-191 boosted alpha-galactosidase A levels in all 11 Fabry patients dosed in a Phase 1/2 U.S. trial (NCT06270316). All participants stopped enzyme replacement therapy. The company reported a manageable safety profile as of June, after prior liver enzyme elevations in two patients resolved with immunosuppression.

$QUREMedAI 8/10

Why is uniQure stock surging today? By Investing.com

uniQure NV (QURE) shares rose about 6.3% pre-market after the company reported 2Q 2026 results and received July 2026 FDA meeting minutes confirming alignment that an AMT-130 BLA submission under accelerated approval using existing clinical data is reasonable. Revenue was $5.84M vs ~$5.49M consensus. uniQure also raised $259M via follow-on offering, extending cash runway to 2030.

$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure N.V. (NASDAQ: QURE) reported Q2 2026 results and updated its gene therapy pipeline. It said FDA alignment supports a Q3 2026 BLA submission for AMT-130 in Huntington’s disease, with four-year Phase I/II data planned for September 2026. For AMT-260, early Phase I/IIa cohort data showed seizure reductions and no AMT-260 related SAEs. uniQure raised $259M via a follow-on offering, extending cash runway into 2030. Q2 revenue was $5.8M.

$QUREMed

uniQure N.V. (QURE): Results of Operations and Financial Condition

uniQure N.V. (QURE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qure-20260729xex99d1.htm EX-99.1 Exhibit 99.1 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline fo

$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure N.V. (Nasdaq: QURE) said it closed an upsized underwritten public offering of 5,686,813 ordinary shares at $45.50 each, including 741,758 shares from full exercise of the underwriters’ option. Gross proceeds were about $259 million before underwriting fees and expenses. Net proceeds will fund AMT-130 commercialization readiness, a confirmatory study, other clinical programs, business development, and general corporate purposes.